Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C10H17N3S.2ClH.H2O |
Molecular Weight | 302.264 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.Cl.Cl.CCCN[C@H]1CCC2=C(C1)SC(N)=N2
InChI
InChIKey=APVQOOKHDZVJEX-QTPLPEIMSA-N
InChI=1S/C10H17N3S.2ClH.H2O/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8;;;/h7,12H,2-6H2,1H3,(H2,11,13);2*1H;1H2/t7-;;;/m0.../s1
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C10H17N3S |
Molecular Weight | 211.327 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00413Curator's Comment: Description was created based on several sources, including
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020667s014s017s018lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB00413
Curator's Comment: Description was created based on several sources, including
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020667s014s017s018lbl.pdf
Pramipexole is a nonergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The relevance of D3 receptor binding in Parkinson's disease is unknown. The precise mechanism of action of Pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have demonstrated that Pramipexole influences striatal neuronal firing rates via activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum.
Pramipexole is used for the treatment of signs and symptoms of idiopathic Parkinson's disease.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL234 Sources: http://www.drugbank.ca/drugs/DB00413 |
1.5 nM [EC50] | ||
Target ID: CHEMBL217 Sources: http://www.drugbank.ca/drugs/DB00413 |
27.0 nM [EC50] | ||
Target ID: CHEMBL219 Sources: http://www.drugbank.ca/drugs/DB00413 |
15.0 nM [EC50] | ||
Target ID: CHEMBL205 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24289818 |
4.81 µM [IC50] | ||
Target ID: CHEMBL261 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24289818 |
5.37 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | MIRAPEX Approved UseMirapex® (pramipexole dihydrochloride) tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
MIRAPEX tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS). Launch Date8.6762881E11 |
|||
Primary | MIRAPEX Approved UseMirapex® (pramipexole dihydrochloride) tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
MIRAPEX tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS). Launch Date8.6762881E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.268 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/20110012 |
0.375 mg single, oral dose: 0.375 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRAMIPEXOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5.29 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/20110012 |
0.375 mg single, oral dose: 0.375 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRAMIPEXOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
31.2 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/20110012 |
0.375 mg single, oral dose: 0.375 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRAMIPEXOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
1.5 mg 3 times / day multiple, oral (max) Recommended Dose: 1.5 mg, 3 times / day Route: oral Route: multiple Dose: 1.5 mg, 3 times / day Sources: Page: p.740 |
unhealthy, 61.6 n = 391 Health Status: unhealthy Condition: Parkinson's disease Age Group: 61.6 Sex: M+F Population Size: 391 Sources: Page: p.740 |
Disc. AE: Hallucination, Hypotension... AEs leading to discontinuation/dose reduction: Hallucination (1.3%) Sources: Page: p.740Hypotension (0.5%) Peripheral edema (0.5%) |
1.5 mg 3 times / day multiple, oral (max) Recommended Dose: 1.5 mg, 3 times / day Route: oral Route: multiple Dose: 1.5 mg, 3 times / day Sources: Page: p.727 |
unhealthy, 62.7 n = 163 Health Status: unhealthy Condition: Parkinson's disease Age Group: 62.7 Sex: M+F Population Size: 163 Sources: Page: p.727 |
Disc. AE: Hallucinations, Sleepiness... AEs leading to discontinuation/dose reduction: Hallucinations (4.3%) Sources: Page: p.727Sleepiness (3%) Dizziness (2.5%) Memory loss (1.2%) Paranoia (0.6%) |
2 mg 3 times / day multiple, oral Highest studied dose Dose: 2 mg, 3 times / day Route: oral Route: multiple Dose: 2 mg, 3 times / day Sources: Page: p.128 |
unhealthy, 62.8 n = 55 Health Status: unhealthy Condition: Parkinson's disease Age Group: 62.8 Sex: M+F Population Size: 55 Sources: Page: p.128 |
DLT: Drowsiness, Muscle spasms... Dose limiting toxicities: Drowsiness (3.6%) Sources: Page: p.128Muscle spasms (1.8%) Insomnia (1.8%) Vertigo (1.8%) Ankle swelling (1.8%) Hallucination (3.6%) Nausea (1.8%) |
1.5 mg 3 times / day multiple, oral (max) Recommended Dose: 1.5 mg, 3 times / day Route: oral Route: multiple Dose: 1.5 mg, 3 times / day Sources: Page: p.740 |
unhealthy, 63 n = 511 Health Status: unhealthy Condition: Parkinson's disease Age Group: 63 Sex: M+F Population Size: 511 Sources: Page: p.740 |
Disc. AE: Nausea, Hallucination... AEs leading to discontinuation/dose reduction: Nausea (0.6%) Sources: Page: p.740Hallucination (1%) Peripheral edema (0.8%) Abdominal pain upper (0.6%) Myocardial infarction (0.6%) Pneumonia (0.6%) Vomiting (0.6%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypotension | 0.5% Disc. AE |
1.5 mg 3 times / day multiple, oral (max) Recommended Dose: 1.5 mg, 3 times / day Route: oral Route: multiple Dose: 1.5 mg, 3 times / day Sources: Page: p.740 |
unhealthy, 61.6 n = 391 Health Status: unhealthy Condition: Parkinson's disease Age Group: 61.6 Sex: M+F Population Size: 391 Sources: Page: p.740 |
Peripheral edema | 0.5% Disc. AE |
1.5 mg 3 times / day multiple, oral (max) Recommended Dose: 1.5 mg, 3 times / day Route: oral Route: multiple Dose: 1.5 mg, 3 times / day Sources: Page: p.740 |
unhealthy, 61.6 n = 391 Health Status: unhealthy Condition: Parkinson's disease Age Group: 61.6 Sex: M+F Population Size: 391 Sources: Page: p.740 |
Hallucination | 1.3% Disc. AE |
1.5 mg 3 times / day multiple, oral (max) Recommended Dose: 1.5 mg, 3 times / day Route: oral Route: multiple Dose: 1.5 mg, 3 times / day Sources: Page: p.740 |
unhealthy, 61.6 n = 391 Health Status: unhealthy Condition: Parkinson's disease Age Group: 61.6 Sex: M+F Population Size: 391 Sources: Page: p.740 |
Paranoia | 0.6% Disc. AE |
1.5 mg 3 times / day multiple, oral (max) Recommended Dose: 1.5 mg, 3 times / day Route: oral Route: multiple Dose: 1.5 mg, 3 times / day Sources: Page: p.727 |
unhealthy, 62.7 n = 163 Health Status: unhealthy Condition: Parkinson's disease Age Group: 62.7 Sex: M+F Population Size: 163 Sources: Page: p.727 |
Memory loss | 1.2% Disc. AE |
1.5 mg 3 times / day multiple, oral (max) Recommended Dose: 1.5 mg, 3 times / day Route: oral Route: multiple Dose: 1.5 mg, 3 times / day Sources: Page: p.727 |
unhealthy, 62.7 n = 163 Health Status: unhealthy Condition: Parkinson's disease Age Group: 62.7 Sex: M+F Population Size: 163 Sources: Page: p.727 |
Dizziness | 2.5% Disc. AE |
1.5 mg 3 times / day multiple, oral (max) Recommended Dose: 1.5 mg, 3 times / day Route: oral Route: multiple Dose: 1.5 mg, 3 times / day Sources: Page: p.727 |
unhealthy, 62.7 n = 163 Health Status: unhealthy Condition: Parkinson's disease Age Group: 62.7 Sex: M+F Population Size: 163 Sources: Page: p.727 |
Sleepiness | 3% Disc. AE |
1.5 mg 3 times / day multiple, oral (max) Recommended Dose: 1.5 mg, 3 times / day Route: oral Route: multiple Dose: 1.5 mg, 3 times / day Sources: Page: p.727 |
unhealthy, 62.7 n = 163 Health Status: unhealthy Condition: Parkinson's disease Age Group: 62.7 Sex: M+F Population Size: 163 Sources: Page: p.727 |
Hallucinations | 4.3% Disc. AE |
1.5 mg 3 times / day multiple, oral (max) Recommended Dose: 1.5 mg, 3 times / day Route: oral Route: multiple Dose: 1.5 mg, 3 times / day Sources: Page: p.727 |
unhealthy, 62.7 n = 163 Health Status: unhealthy Condition: Parkinson's disease Age Group: 62.7 Sex: M+F Population Size: 163 Sources: Page: p.727 |
Ankle swelling | 1.8% DLT |
2 mg 3 times / day multiple, oral Highest studied dose Dose: 2 mg, 3 times / day Route: oral Route: multiple Dose: 2 mg, 3 times / day Sources: Page: p.128 |
unhealthy, 62.8 n = 55 Health Status: unhealthy Condition: Parkinson's disease Age Group: 62.8 Sex: M+F Population Size: 55 Sources: Page: p.128 |
Insomnia | 1.8% DLT |
2 mg 3 times / day multiple, oral Highest studied dose Dose: 2 mg, 3 times / day Route: oral Route: multiple Dose: 2 mg, 3 times / day Sources: Page: p.128 |
unhealthy, 62.8 n = 55 Health Status: unhealthy Condition: Parkinson's disease Age Group: 62.8 Sex: M+F Population Size: 55 Sources: Page: p.128 |
Muscle spasms | 1.8% DLT |
2 mg 3 times / day multiple, oral Highest studied dose Dose: 2 mg, 3 times / day Route: oral Route: multiple Dose: 2 mg, 3 times / day Sources: Page: p.128 |
unhealthy, 62.8 n = 55 Health Status: unhealthy Condition: Parkinson's disease Age Group: 62.8 Sex: M+F Population Size: 55 Sources: Page: p.128 |
Nausea | 1.8% DLT |
2 mg 3 times / day multiple, oral Highest studied dose Dose: 2 mg, 3 times / day Route: oral Route: multiple Dose: 2 mg, 3 times / day Sources: Page: p.128 |
unhealthy, 62.8 n = 55 Health Status: unhealthy Condition: Parkinson's disease Age Group: 62.8 Sex: M+F Population Size: 55 Sources: Page: p.128 |
Vertigo | 1.8% DLT |
2 mg 3 times / day multiple, oral Highest studied dose Dose: 2 mg, 3 times / day Route: oral Route: multiple Dose: 2 mg, 3 times / day Sources: Page: p.128 |
unhealthy, 62.8 n = 55 Health Status: unhealthy Condition: Parkinson's disease Age Group: 62.8 Sex: M+F Population Size: 55 Sources: Page: p.128 |
Drowsiness | 3.6% DLT |
2 mg 3 times / day multiple, oral Highest studied dose Dose: 2 mg, 3 times / day Route: oral Route: multiple Dose: 2 mg, 3 times / day Sources: Page: p.128 |
unhealthy, 62.8 n = 55 Health Status: unhealthy Condition: Parkinson's disease Age Group: 62.8 Sex: M+F Population Size: 55 Sources: Page: p.128 |
Hallucination | 3.6% DLT |
2 mg 3 times / day multiple, oral Highest studied dose Dose: 2 mg, 3 times / day Route: oral Route: multiple Dose: 2 mg, 3 times / day Sources: Page: p.128 |
unhealthy, 62.8 n = 55 Health Status: unhealthy Condition: Parkinson's disease Age Group: 62.8 Sex: M+F Population Size: 55 Sources: Page: p.128 |
Abdominal pain upper | 0.6% Disc. AE |
1.5 mg 3 times / day multiple, oral (max) Recommended Dose: 1.5 mg, 3 times / day Route: oral Route: multiple Dose: 1.5 mg, 3 times / day Sources: Page: p.740 |
unhealthy, 63 n = 511 Health Status: unhealthy Condition: Parkinson's disease Age Group: 63 Sex: M+F Population Size: 511 Sources: Page: p.740 |
Myocardial infarction | 0.6% Disc. AE |
1.5 mg 3 times / day multiple, oral (max) Recommended Dose: 1.5 mg, 3 times / day Route: oral Route: multiple Dose: 1.5 mg, 3 times / day Sources: Page: p.740 |
unhealthy, 63 n = 511 Health Status: unhealthy Condition: Parkinson's disease Age Group: 63 Sex: M+F Population Size: 511 Sources: Page: p.740 |
Nausea | 0.6% Disc. AE |
1.5 mg 3 times / day multiple, oral (max) Recommended Dose: 1.5 mg, 3 times / day Route: oral Route: multiple Dose: 1.5 mg, 3 times / day Sources: Page: p.740 |
unhealthy, 63 n = 511 Health Status: unhealthy Condition: Parkinson's disease Age Group: 63 Sex: M+F Population Size: 511 Sources: Page: p.740 |
Pneumonia | 0.6% Disc. AE |
1.5 mg 3 times / day multiple, oral (max) Recommended Dose: 1.5 mg, 3 times / day Route: oral Route: multiple Dose: 1.5 mg, 3 times / day Sources: Page: p.740 |
unhealthy, 63 n = 511 Health Status: unhealthy Condition: Parkinson's disease Age Group: 63 Sex: M+F Population Size: 511 Sources: Page: p.740 |
Vomiting | 0.6% Disc. AE |
1.5 mg 3 times / day multiple, oral (max) Recommended Dose: 1.5 mg, 3 times / day Route: oral Route: multiple Dose: 1.5 mg, 3 times / day Sources: Page: p.740 |
unhealthy, 63 n = 511 Health Status: unhealthy Condition: Parkinson's disease Age Group: 63 Sex: M+F Population Size: 511 Sources: Page: p.740 |
Peripheral edema | 0.8% Disc. AE |
1.5 mg 3 times / day multiple, oral (max) Recommended Dose: 1.5 mg, 3 times / day Route: oral Route: multiple Dose: 1.5 mg, 3 times / day Sources: Page: p.740 |
unhealthy, 63 n = 511 Health Status: unhealthy Condition: Parkinson's disease Age Group: 63 Sex: M+F Population Size: 511 Sources: Page: p.740 |
Hallucination | 1% Disc. AE |
1.5 mg 3 times / day multiple, oral (max) Recommended Dose: 1.5 mg, 3 times / day Route: oral Route: multiple Dose: 1.5 mg, 3 times / day Sources: Page: p.740 |
unhealthy, 63 n = 511 Health Status: unhealthy Condition: Parkinson's disease Age Group: 63 Sex: M+F Population Size: 511 Sources: Page: p.740 |
PubMed
Title | Date | PubMed |
---|---|---|
Pramipexole treatment for cocaine cravings. | 1999 Nov |
|
Role of dopamine D3 receptors in thermoregulation: a reappraisal. | 2000 Jan 17 |
|
Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials. | 2001 |
|
Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. | 2001 Jul |
|
Current and emerging treatments in Parkinson's disease. | 2001 Mar |
|
Newer dopamine agonists in the treatment of restless legs syndrome. | 2001 May |
|
DA agonists -- non-ergot derivatives: pramipexole: management of Parkinson's disease. | 2002 |
|
Acute placebo-controlled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome. | 2002 Aug |
|
Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. | 2002 Dec 24 |
|
A review of pramipexole and its clinical utility in Parkinson's disease. | 2002 Feb |
|
Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma. | 2002 Feb 15 |
|
Neuroprotection and dopamine agonists. | 2002 Feb 26 |
|
Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. | 2002 Jan 23-30 |
|
Pergolide in the treatment of patients with early and advanced Parkinson's disease. | 2002 Jan-Feb |
|
Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. | 2002 Jun |
|
A case of Parkinsonism due to lithium intoxication: treatment with Pramipexole. | 2002 May |
|
Restless legs syndrome augmentation and pramipexole treatment. | 2002 Nov |
|
Dopamine agonists and neuroprotection in Parkinson's disease. | 2002 Nov |
|
Effect of daily dosing duration of direct and indirect dopamine receptor agonists: cocaine cross-tolerance following chronic regimens. | 2002 Oct |
|
Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. | 2003 |
|
Sleepwalking and sleep terrors in prepubertal children: what triggers them? | 2003 Jan |
|
Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists. | 2003 Jul |
|
Parkinson's disease: is the initial treatment established? | 2003 Jul |
|
Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists. | 2003 May |
|
Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. | 2003 Nov |
|
Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease. | 2003 Oct |
Sample Use Guides
Dosages should be increased gradually from a starting dose of 0.375 mg/day given in three divided doses and should not be increased more frequently than every 5 to 7 days.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26213307
Pramipexole suppressed H2O2-induced ARPE-19 cell death in vitro at concentrations of 10(-6) M or higher.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 17:16:33 UTC 2022
by
admin
on
Fri Dec 16 17:16:33 UTC 2022
|
Record UNII |
3D867NP06J
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
PRAMIPEXOLE ACCORD (AUTHORIZED: RESTLESS LEGS SYNDROME)
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
MIRAPEXIN (AUTHORIZED: RESTLESS LEGS SYNDROME)
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
PRAMIPEXOLE TEVA (AUTHORIZED: PARKINSON DISEASE)
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
SIFROL (AUTHORIZED: RESTLESS LEGS SYNDROME)
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
MIRAPEXIN (AUTHORIZED: PARKINSON DISEASE)
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
PRAMIPEXOLE ACCORD (AUTHORIZED: PARKINSON DISEASE)
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
||
|
NCI_THESAURUS |
C66884
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
OPRYMEA (AUTHORIZED: PARKINSON DISEASE)
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
DAQUIRAN (WITHDRAWN: PARKINSON DISEASE)
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
SIFROL (AUTHORIZED: PARKINSON DISEASE)
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
||
|
NCI_THESAURUS |
C38149
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID1044227
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
PRIMARY | |||
|
1553859
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
PRIMARY | |||
|
236747
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
PRIMARY | RxNorm | ||
|
191217-81-9
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
PRIMARY | |||
|
3D867NP06J
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
PRIMARY | |||
|
CHEMBL301265
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
PRIMARY | |||
|
51147
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
PRIMARY | |||
|
51148
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
PRIMARY | |||
|
DBSALT001198
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
PRIMARY | |||
|
SUB25197
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
PRIMARY | |||
|
C29374
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
PRIMARY | |||
|
KK-01
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
PRIMARY | |||
|
SUB12563MIG
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
PRIMARY | |||
|
166589
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
PRIMARY | |||
|
3D867NP06J
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
PRIMARY | |||
|
M9095
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
PRIMARY | Merck Index | ||
|
SUB04004MIG
Created by
admin on Fri Dec 16 17:16:33 UTC 2022 , Edited by admin on Fri Dec 16 17:16:33 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
PARENT -> SALT/SOLVATE | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
ANHYDROUS->SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |